Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)

Bang Y.-J.Golan T.Dahan L.Fu S.Moreno V.Park K.Geva R.De Braud F.Wainberg Z.A.Reck M.Goff L.Laing N.Mi G.Oliveira J.M.Wasserstrom H.CHIA-CHI LIN2022-09-152022-09-1520200959-8049https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089519572&doi=10.1016%2fj.ejca.2020.06.007&partnerID=40&md5=b4269f5613e16888ccfba8d0e1260daehttps://scholars.lib.ntu.edu.tw/handle/123456789/620228[SDGs]SDG3Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)journal article10.1016/j.ejca.2020.06.007328278472-s2.0-85089519572